Free Trial
NYSEAMERICAN:PTN

Palatin Technologies Q3 2026 Earnings Report

$19.47 +0.57 (+3.02%)
Closing price 04:10 PM Eastern
Extended Trading
$19.50 +0.03 (+0.13%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palatin Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$1.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Palatin Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.28 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Palatin Technologies Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
11:00AM ET

Conference Call Resources

Palatin Technologies Earnings Headlines

The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
See More Palatin Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palatin Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palatin Technologies and other key companies, straight to your email.

About Palatin Technologies

Palatin Technologies (NYSEAMERICAN:PTN), Inc. (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization. Its pipeline has historically included multiple candidate programs at various stages of development, and the company has sought to progress those programs through clinical trials while evaluating potential collaborations to broaden development resources and market access.

Palatin operates in the United States and engages with the broader biopharma ecosystem to advance its products. Publicly traded on the NYSE American exchange, the company has worked to leverage scientific expertise and external partnerships to move assets forward. I do not have fully verifiable, up-to-date details on current executive leadership or recent corporate milestones; readers should consult the company’s filings and official releases for the latest leadership, pipeline and strategic information.

View Palatin Technologies Profile